OncoTalks | Oncology Insights at Your Fingertips

Epizode

• 
  Micro-Series | Part 4 | Beyond Breast Cancer Treatment Selection: Supporting Adherence and Quality of Life 16.10.2026 4min

  In this concluding episode, Dr. Mabel Mardones shares practical approaches to managing treatment-related toxicities, supporting adherence, and maintaining quality of life, emphasizing proactive intervention, individualized support, and patient centricity throughout breast cancer care. This episode is part of the micro-series, Advancing Personalized Care in HR+/HER2− Breast Cancer. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 3 | Biomarker-Driven Treatment Sequencing in Metastatic Breast Cancer 16.10.2026 4min

  In this episode of OncoTalks, Dr. Mabel Mardones examines how endocrine sensitivity, biomarker testing, and evolving resistance biology inform treatment sequencing in metastatic HR-positive/HER2-negative breast cancer, including the growing role of molecular monitoring and targeting ESR1 alterations to individualize care. This episode is part of the micro-series, Advancing Personalized Care in HR+/HER2− Breast Cancer. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 2 | Choosing a CDK4/6 Inhibitor in Early-Stage Breast Cancer 16.10.2026 4min

  In this episode of OncoTalks, Dr. Mabel Mardones explains how treatment duration, toxicity profiles, and patient-specific factors can inform CDK4/6 inhibitor selection in early-stage HR-positive/HER2-negative breast cancer, while examining emerging endocrine therapies that may shape future treatment strategies. This episode is part of the micro-series, Advancing Personalized Care in HR+/HER2− Breast Cancer. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 1 | Personalizing Treatment in Early-Stage HR+/HER2− Breast Cancer 16.10.2026 4min

  In this episode of OncoTalks, Dr. Mabel Mardones discusses how clinical features, genomic risk, and patient priorities inform treatment planning in early-stage HR-positive/HER2-negative breast cancer, including considerations for chemotherapy, endocrine therapy, and CDK4/6 inhibition. This episode is part of the micro-series, Advancing Personalized Care in HR+/HER2− Breast Cancer. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Evolving CLL Care: What Long-Term Data Teach Us About BTK Inhibitors 09.10.2026 12min

  In this episode of OncoTalks, host Dr. Ira Zackon welcomes Dr. Brad Christensen to discuss how mature clinical trial data are influencing treatment selection and patient management in CLL. Together, they explore the importance of long-term disease control, tolerability and safety considerations, and the factors that guide decisions between continuous and time-limited treatment approaches. The conversation also examines the remaining questions in the field, ongoing research into MRD-guided therapy, and what the future may hold for treatment sequencing, therapeutic re-challenge, BTK degraders, bispecific antibodies, and new therapeutic strategies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Long-Term BTKi Success: Adherence, Dosing, and Patient Support in CLL 25.09.2026 15min

  Adherence starts long before the first missed dose. In this episode, Dr. Brad Christensen shares real-world insights on helping patients with chronic lymphocytic leukemia (CLL) stay on BTK inhibitor therapy over the long term. Topics include individualized treatment selection, the role of dosing flexibility in real-world practice, and proactive adverse event management. Dr. Christensen also highlights the importance of frequent early follow-up, patient education, and home monitoring to support treatment continuity and optimize outcomes throughout the patient journey. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 4 | Optimizing Long-Term TKI Therapy in Resistant CML 04.09.2026 4min

  In the final installment, Dr. Luke Fletcher shares strategies for managing resistant chronic myeloid leukemia (CML), including adverse event monitoring, supportive care, and response-based dose optimization to improve long-term treatment success. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 3 | Managing Resistance in CML: When and Why to Test for BCR-ABL1 Mutations 04.09.2026 3min

  Dr. Luke Fletcher discusses mutation testing in chronic myeloid leukemia (CML), including when to test, how results influence treatment decisions, and the clinical significance of mutations such as T315I. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 2 | Measuring Molecular Response in Ph+ ALL 28.08.2026 3min

  Dr. Luke Fletcher examines the growing role of measurable residual disease (MRD) and molecular response in treatment monitoring, and the impact of tyrosine kinase inhibitor (TKI) selection on achieving deep and durable responses for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 1 | TKIs in Frontline Ph+ ALL Treatment 28.08.2026 4min

  Dr. Luke Fletcher reviews the evolving treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), highlighting how tyrosine kinase inhibitors (TKIs) are integrated throughout induction, consolidation, and maintenance therapy to support long-term disease control. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 4 | The Next Evolution in Anti-CD38 Therapy: On-Body Injector Technology 21.08.2026 3min

  Dr. Edward Pearson explores the latest advancement in anti-CD38 therapy: subcutaneous delivery of isatuximab via on-body injector. He reviews clinical evidence on efficacy, safety, and patient preference, and shares how he anticipates this innovation to impact clinic workflows, care teams, and the overall multiple myeloma patient experience. This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 3 | The Nursing Perspective on Subcutaneous Anti-CD38 Therapy 21.08.2026 4min

  Brook Cox, BSN, RN, OCN, an oncology nurse and infusion room supervisor, shares how subcutaneous administration of anti-CD38 therapy has transformed infusion center operations, improved patient flow, and created both opportunities and challenges for nursing teams caring for patients with multiple myeloma. This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 2 | Frontline Treatment Optimization in High-Risk and Transplant-Ineligible Multiple Myeloma 14.08.2026 3min

  Dr. Edward Pearson reviews pivotal clinical trial data supporting anti-CD38-based regimens and explores how clinicians can balance efficacy, tolerability, and quality of life when managing high-risk and transplant-ineligible multiple myeloma. This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 1 | Navigating Care for Transplant-Ineligible Multiple Myeloma Patients 14.08.2026 4min

  Dr. Edward Pearson discusses the growing role of anti-CD38-based quadruplet therapy and key considerations influencing frontline therapy selection for patients with newly diagnosed, transplant-ineligible multiple myeloma. This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  HER2 Testing in Solid Tumors 05.08.2026 1min

  This learning module provides a brief overview of HER2 testing in metastatic non-small cell lung, bladder, rectal, cervical, biliary tract, ovarian, pancreatic, endometrial, and colon cancers, highlighting disease-specific testing approaches, interpretation of HER2 results, and key dosing and safety monitoring considerations. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Provider Perspectives on BTKi Selection in CLL 22.07.2026 12min

  In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of second-generation BTK inhibitors, and the importance of tailoring treatment to individual patient characteristics. The discussion also explores the challenges providers face when navigating insurance requirements, medication access, and long-term adherence. Learn how thoughtful treatment selection and patient-centered education can help improve outcomes throughout the CLL treatment journey. Listen to Navigating the CLL Treatment Landscape: The Role of Physician Choice as Dr. Levy discusses why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Navigating the CLL Treatment Landscape: The Role of Physician Choice 13.07.2026 7min

  In this episode of OncoTalks, host Tulsi Patel is joined by Dr. Yair Levy to discuss the growing impact of utilization management policies on chronic lymphocytic leukemia (CLL) care. As treatment options expand, personalized therapy selection is more critical than ever, yet step therapy requirements and payer restrictions are increasingly shaping clinical decisions. Dr. Levy shares real-world insights on how these policies affect patient outcomes, treatment adherence, and provider workload. Tune in to explore why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Case Journey | EP-NEC in Focus: A Case-Based Look at Unmet Needs and DLL3-Targeted Therapy 19.06.2026 7min

  Follow the clinical journey of extrapulmonary neuroendocrine carcinoma (EP-NEC) through a real-world patient case presented by Dr. Deepak Bhamidipati. This episode explores key diagnostic considerations, gaps in current treatment, and the need for more durable therapeutic options. Learn how emerging DLL3-targeted therapies, including the DLL3/CD3 T-cell engager, obrixtamig, are showing promise in clinical trials and may reshape the future of EP-NEC management. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 4 | DLL3 in EP-NEC: A New Therapeutic Target Comes Into Focus 24.04.2026 4min

  Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Meredith Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers. This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
• 
  Micro-Series | Part 3 | What’s Next for EP-NEC: New Therapies on the Horizon 24.04.2026 4min

  With limited durable options available, new approaches are urgently needed in EP-NEC. Dr. Meredith Pelster highlights emerging therapies, including immunotherapy‑based strategies and early clinical trial data shaping future treatment directions. This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.